CheckMyRecalls

10,013 recalls · updated 20 Nov 2026

Regeneron Pharmaceuticals Inc recalls Libtayo (cemiplimab-rwlc)…

Regeneron Pharmaceuticals Inc recalls Libtayo (cemiplimab-rwlc) Injection

Read the official FDA notice

Published
26 Aug 2026
Units affected
21,353 vials
Agency
FDA
Country
United States

The hazard

Lack of Assurance of Sterility

Classification: Class II — this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.

What to do

Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.

  • Check the lot number on the box or bottle.
  • Talk to your pharmacist or doctor before stopping any prescribed medicine.
  • Return the product to the pharmacy for safe disposal.
Read the official FDA notice

Product details

Libtayo (cemiplimab-rwlc) Injection, 350 mg/7 mL (50 mg/mL), For Intravenous Infusion After Dilution, Single-Dose Vial, Rx only, Manufactured by: Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591; Marketed by: Regeneron Pharmaceuticals, Inc. (Tarrytown, NY 10591), NDC 61755-008-01

Brand / company
Regeneron Pharmaceuticals Inc
Codes / lots
Lot: 8494000002, Exp 7/31/28
Distribution
USA Nationwide
Recall status
Ongoing

Source: U.S. Food and Drug Administration, published 26 Aug 2026. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.